These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28169005)

  • 41. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
    Karthik U; Motwani J
    J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
    Berg SL; Blaney SM; Devidas M; Lampkin TA; Murgo A; Bernstein M; Billett A; Kurtzberg J; Reaman G; Gaynon P; Whitlock J; Krailo M; Harris MB;
    J Clin Oncol; 2005 May; 23(15):3376-82. PubMed ID: 15908649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
    Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A nelarabine-resistant T-lymphoblastic leukemia CCRF-CEM variant cell line is cross-resistant to the purine nucleoside phosphorylase inhibitor forodesine.
    Yamauchi T; Uzui K; Nishi R; Tasaki T; Ueda T
    Anticancer Res; 2014 Sep; 34(9):4885-92. PubMed ID: 25202070
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival.
    Forcade E; Leguay T; Vey N; Baruchel A; Delaunay J; Robin M; Socié G; Dombret H; Peffault de Latour R; Raffoux E
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1124-6. PubMed ID: 23648236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
    Kisor DF
    Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nelarabine associated myotoxicity and rhabdomyolysis.
    Haider M; Rizvi SA; Kasi PM
    Case Rep Hematol; 2015; 2015():825670. PubMed ID: 25866685
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
    Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
    Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.
    Cooper TM
    Ther Clin Risk Manag; 2007 Dec; 3(6):1135-41. PubMed ID: 18516261
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nelarabine-induced peripheral and central neurotoxicity: can sequential MRI brain imaging help to define its natural history?
    Ewins K; Malone A; Phelan E; Webb D; McHugh JC; Smith O
    Br J Haematol; 2017 Oct; 179(2):294-297. PubMed ID: 28961308
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
    Shimony S; DeAngelo DJ; Luskin MR
    Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
    Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
    Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
    Czuczman MS; Porcu P; Johnson J; Niedzwiecki D; Kelly M; Hsi ED; Cook JR; Canellos G; Cheson BD;
    Leuk Lymphoma; 2007 Jan; 48(1):97-103. PubMed ID: 17325852
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
    Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
    Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Guillain-Barré syndrome after bortezomib therapy in a child with relapsed acute lymphoblastic leukemia.
    Ceolin V; Cenna R; Resente F; Spadea M; Fagioli F; Bertorello N
    Pediatr Hematol Oncol; 2022 Mar; 39(2):187-192. PubMed ID: 34369835
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.
    Kurtzberg J; Ernst TJ; Keating MJ; Gandhi V; Hodge JP; Kisor DF; Lager JJ; Stephens C; Levin J; Krenitsky T; Elion G; Mitchell BS
    J Clin Oncol; 2005 May; 23(15):3396-403. PubMed ID: 15908652
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Guillain-Barré syndrome in a case of acute lymphoblastic leukaemia. A case report.
    Vembu P; Al-Shubaili A; Al-Khuraibet A; Kreze O; Pandita R
    Med Princ Pract; 2003; 12(4):272-5. PubMed ID: 12966204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
    Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.